Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease.


Journal

Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215

Informations de publication

Date de publication:
09 07 2021
Historique:
received: 04 02 2020
revised: 22 02 2021
accepted: 15 04 2021
entrez: 23 7 2021
pubmed: 24 7 2021
medline: 24 7 2021
Statut: ppublish

Résumé

Evidence suggests an important role for gut-microbiota dysbiosis in the development of rheumatoid arthritis (RA). The link between changes in gut bacteria and the development of joint inflammation is missing. Here, we address whether there are changes to the gut environment and how they contribute to arthritis pathogenesis. We analyzed changes in markers of gut permeability, damage, and inflammation in peripheral blood and serum of RA patients. Serum, intestines, and lymphoid organs isolated from K/BxN mice with spontaneous arthritis or from wild-type, genetically modified interleukin (IL)-10R RA patients display increased levels of serum markers of gut permeability and We suggest that breakdown of gut-barrier integrity contributes to arthritis development and propose restoration of gut-barrier homeostasis as a new therapeutic approach for RA. Funded by Versus Arthritis (21140 and 21257) and UKRI/MRC (MR/T000910/1).

Sections du résumé

BACKGROUND
Evidence suggests an important role for gut-microbiota dysbiosis in the development of rheumatoid arthritis (RA). The link between changes in gut bacteria and the development of joint inflammation is missing. Here, we address whether there are changes to the gut environment and how they contribute to arthritis pathogenesis.
METHODS
We analyzed changes in markers of gut permeability, damage, and inflammation in peripheral blood and serum of RA patients. Serum, intestines, and lymphoid organs isolated from K/BxN mice with spontaneous arthritis or from wild-type, genetically modified interleukin (IL)-10R
FINDINGS
RA patients display increased levels of serum markers of gut permeability and
CONCLUSIONS
We suggest that breakdown of gut-barrier integrity contributes to arthritis development and propose restoration of gut-barrier homeostasis as a new therapeutic approach for RA.
FUNDING
Funded by Versus Arthritis (21140 and 21257) and UKRI/MRC (MR/T000910/1).

Identifiants

pubmed: 34296202
doi: 10.1016/j.medj.2021.04.013
pii: S2666-6340(21)00162-8
pmc: PMC8280953
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

864-883.e9

Subventions

Organisme : Versus Arthritis
ID : 21140
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T000910/1
Pays : United Kingdom

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

A.F. is co-founder and stockholder of Alba Therapeutics, a company developing treatments complementary to the gluten-free diet by exploiting gut permeability.

Références

J Rheumatol. 1991 Mar;18(3):389-93
pubmed: 1906938
Br J Rheumatol. 1986 May;25(2):162-6
pubmed: 3085760
Adv Immunol. 2014;122:177-210
pubmed: 24507158
J Cell Biol. 1986 Sep;103(3):755-66
pubmed: 3528172
Nat Commun. 2020 Apr 24;11(1):1995
pubmed: 32332732
Am J Physiol Gastrointest Liver Physiol. 2013 Sep 1;305(5):G357-63
pubmed: 23832516
Front Immunol. 2018 Jun 05;9:1270
pubmed: 29922293
Am J Physiol Gastrointest Liver Physiol. 2017 Mar 1;312(3):G171-G193
pubmed: 27908847
Clin Chem. 2008 Apr;54(4):697-704
pubmed: 18258668
Arthritis Rheumatol. 2017 May;69(5):964-975
pubmed: 27863183
Genome Med. 2016 Apr 21;8(1):43
pubmed: 27102666
J Clin Med. 2019 Nov 01;8(11):
pubmed: 31683983
Cell Metab. 2020 Apr 7;31(4):837-851.e10
pubmed: 32213346
Mult Scler. 2020 Oct;26(11):1340-1350
pubmed: 31317818
J Immunol. 2003 Dec 1;171(11):6164-72
pubmed: 14634132
J Clin Med. 2019 May 16;8(5):
pubmed: 31100891
J Proteome Res. 2017 Jan 6;16(1):346-354
pubmed: 27627584
FASEB J. 2005 Jun;19(8):923-33
pubmed: 15923402
Mult Scler. 2017 Mar;23(3):442-446
pubmed: 27270497
J Clin Med. 2017 Jun 09;6(6):
pubmed: 28598360
J Rheumatol. 1985 Apr;12(2):299-305
pubmed: 4032403
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
J Immunol Res. 2017;2017:4835189
pubmed: 28948174
Nat Commun. 2016 May 19;7:11627
pubmed: 27193261
Cell. 1996 Nov 29;87(5):811-22
pubmed: 8945509
J Immunol. 2014 Feb 1;192(3):1267-76
pubmed: 24367025
Biomed Rep. 2013 Mar;1(2):177-184
pubmed: 24648915
J Rheumatol. 1991 Mar;18(3):394-400
pubmed: 1906939
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Ann Rheum Dis. 2017 Jun;76(6):1123-1132
pubmed: 28069576
Nat Mater. 2021 Feb;20(2):250-259
pubmed: 32895507
Scand J Rheumatol. 1997;26(2):92-8
pubmed: 9137322
J Immunol. 2016 Feb 15;196(4):1550-7
pubmed: 26783341
Mediators Inflamm. 2015;2015:628340
pubmed: 26457007
Liver Int. 2019 Feb;39(2):371-381
pubmed: 30269440
Elife. 2013 Nov 05;2:e01202
pubmed: 24192039
Immunity. 2004 Oct;21(4):527-38
pubmed: 15485630
Am J Pathol. 2018 May;188(5):1183-1194
pubmed: 29454749
Lancet. 1984 Nov 24;2(8413):1171-4
pubmed: 6150232
Diabetologia. 2006 Dec;49(12):2824-7
pubmed: 17028899
Int Immunol. 2000 Feb;12(2):133-9
pubmed: 10653848
J Allergy Clin Immunol. 2009 Jul;124(1):3-20; quiz 21-2
pubmed: 19560575
Physiol Rev. 2011 Jan;91(1):151-75
pubmed: 21248165
J Mol Med (Berl). 2017 Sep;95(9):927-934
pubmed: 28707083
Nat Med. 2014 Nov;20(11):1334-9
pubmed: 25326801
J Rheumatol. 2017 Nov;44(11):1624-1631
pubmed: 28916545
Int J Mol Sci. 2018 Sep 27;19(10):
pubmed: 30261687
Arthritis Rheumatol. 2016 Nov;68(11):2646-2661
pubmed: 27333153
Cell. 2004 Jul 23;118(2):229-41
pubmed: 15260992
Blood. 2001 Nov 1;98(9):2626-32
pubmed: 11675330
J Clin Invest. 2008 Mar;118(3):1132-42
pubmed: 18259614
JCI Insight. 2019 Jul 11;4(13):
pubmed: 31292292
Int J Clin Exp Pathol. 2014 Jul 15;7(8):4557-76
pubmed: 25197329
J Biol Chem. 2009 Oct 16;284(42):29205-17
pubmed: 19690347
Nat Med. 2015 Aug;21(8):895-905
pubmed: 26214836
Nat Commun. 2018 Feb 15;9(1):684
pubmed: 29449556
Cytoskeleton (Hoboken). 2016 Apr;73(4):163-79
pubmed: 26972322
Gastroenterology. 2006 Oct;131(4):1153-63
pubmed: 17030185
Immunity. 2010 Jun 25;32(6):815-27
pubmed: 20620945
Clin Chim Acta. 2005 Feb;352(1-2):15-35
pubmed: 15653098
Front Med (Lausanne). 2018 Dec 14;5:349
pubmed: 30619860
Gut. 2007 Jan;56(1):61-72
pubmed: 16822808
Ann N Y Acad Sci. 2012 Jul;1258:25-33
pubmed: 22731712
J Exp Med. 2016 Jun 27;213(7):1223-39
pubmed: 27325889
Int J Mol Sci. 2018 Jul 31;19(8):
pubmed: 30065229
Biomolecules. 2019 Jul 31;9(8):
pubmed: 31370242
Microorganisms. 2018 Aug 02;6(3):
pubmed: 30072673
Gastroenterology. 2015 Jun;148(7):1311-9.e6
pubmed: 25683116

Auteurs

Diana E Matei (DE)

Centre for Rheumatology, Division of Medicine and Division of Infection and Immunity and Transplantation, University College London, London WC1E 6JF, UK.

Madhvi Menon (M)

Centre for Rheumatology, Division of Medicine and Division of Infection and Immunity and Transplantation, University College London, London WC1E 6JF, UK.
Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, MA 02115, USA.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Lydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester M13 9PL, UK.

Dagmar G Alber (DG)

Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.

Andrew M Smith (AM)

Eastman Dental Institute, School of Life and Medical Sciences, UCL, London WC1X 8LD, UK.

Bahman Nedjat-Shokouhi (B)

Eastman Dental Institute, School of Life and Medical Sciences, UCL, London WC1X 8LD, UK.
Centre for Molecular Medicine, Division of Medicine, UCL, London WC1E 6BT, UK.

Alessio Fasano (A)

MassGeneral Hospital for Children, Boston, MA 02114, USA.

Laura Magill (L)

Centre for Rheumatology, Division of Medicine and Division of Infection and Immunity and Transplantation, University College London, London WC1E 6JF, UK.

Amanda Duhlin (A)

Centre for Rheumatology, Division of Medicine and Division of Infection and Immunity and Transplantation, University College London, London WC1E 6JF, UK.

Samuel Bitoun (S)

Rheumatology Department, Bicêtre Hospital AP-HP, Université Paris-Saclay and INSERM UMR 1184 IMVA 78 Avenue du Général Leclerc, 94270 Le Kremlin Bicêtre, France.

Aude Gleizes (A)

Université de Paris, CNRS, INSERM, UTCBS, Unité des Technologies Chimiques et Biologiques pour la Santé, 75006 Paris, France.
Clinical Immunology Laboratory, Groupe Hospitalier Universitaire Paris-Sud, Hôpital Kremlin-Bicêtre, Assistance Publique-Hôpitaux de Paris, 94270 Le-Kremlin-Bicêtre, France.

Salima Hacein-Bey-Abina (S)

Université de Paris, CNRS, INSERM, UTCBS, Unité des Technologies Chimiques et Biologiques pour la Santé, 75006 Paris, France.
Assistance Publique - Hôpitaux Paris Saclay, Clinical Immunology Laboratory, Hôpital Bicêtre, 94275 Le-Kremlin-Bicêtre, France.

Jessica J Manson (JJ)

Department of Rheumatology, University College London Hospital, London NW1 2BU, UK.

Elizabeth C Rosser (EC)

Centre for Rheumatology, Division of Medicine and Division of Infection and Immunity and Transplantation, University College London, London WC1E 6JF, UK.
Centre for Adolescent Rheumatology Versus Arthritis at UCL, UCLH and GOSH, London WC1E 6JF, UK.

Nigel Klein (N)

Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.

Paul A Blair (PA)

Centre for Rheumatology, Division of Medicine and Division of Infection and Immunity and Transplantation, University College London, London WC1E 6JF, UK.

Claudia Mauri (C)

Centre for Rheumatology, Division of Medicine and Division of Infection and Immunity and Transplantation, University College London, London WC1E 6JF, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH